John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.
Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.
Lajos Pusztai, MD, DPhil, professor of Medicine (Medical Oncology), chief, Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses the Breast Cancer Index in patients with ER-positive/HR-positive breast cancer.
Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.
Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.
Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.
Shannon Puhalla, MD Assistant Professor of Medicine, Division of Hematology, University of Pittsburgh, discusses recent updates of the PALOMA-3 trial.
Dicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.
Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.
Walter J. Curran, Jr., MD, Executive Director, Winship Cancer Institute of Emory University, Associate Vice President, Woodruff Health Sciences Center, discusses new developments in the delivery of radiation for patients with lung cancer.
Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.
Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses which patients with breast cancer are most likely to benefit from endocrine therapy.
Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.
Peter Krein, PhD, senior director, Medical and Scientific Affairs, QIAGEN, discusses the company's latest advancements in liquid biopsies in comparison to surgical biopsies.
Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.
Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.
Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.
Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.
Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.
Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.
Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.
Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.
Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.
Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.
Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.
Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.
George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).
Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.
